Contact
searchSearch
HMP Global
Login

September/October 2015

Department

Meet the Board
Meet the JCP Editorial Advisory Board
10/29/2015
Led by Editor-in-Chief Winston Wong, PharmD, the Editorial Advisory Board will advise Journal of Clinical Pathways Editors on the editorial direction of the journal to ensure that its mission of presenting the timeliest and highest quality...
Led by Editor-in-Chief Winston Wong, PharmD, the Editorial Advisory Board will advise Journal of Clinical Pathways Editors on the editorial direction of the journal to ensure that its mission of presenting the timeliest and highest quality...
Led by Editor-in-Chief Winston...
10/29/2015
Journal of Clinical Pathways
Research in Review
Research in Review
10/29/2015
J Clin Pathways. 2016;2(1):9-12. Impact of Alternative Payment Models on Personalized Medicine Personalized medicine is changing the landscape in the battle against cancer. In the midst of this progress, is the trend toward value-based...
J Clin Pathways. 2016;2(1):9-12. Impact of Alternative Payment Models on Personalized Medicine Personalized medicine is changing the landscape in the battle against cancer. In the midst of this progress, is the trend toward value-based...
J Clin Pathways....
10/29/2015
Journal of Clinical Pathways
Conferences
2015 National Association of Specialty Pharmacy Annual Meeting & Expo
10/27/2015
JCP Editors
The National Association of Specialty Pharmacy is a trade association dedicated to education, national policy advocacy, and engagement of all stakeholders in the specialty pharmacy industry.
The National Association of Specialty Pharmacy is a trade association dedicated to education, national policy advocacy, and engagement of all stakeholders in the specialty pharmacy industry.
The National Association of...
10/27/2015
Journal of Clinical Pathways

Feature

Perspectives
The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products
10/28/2015
In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.
In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.
In this article, the authors...
10/28/2015
Journal of Clinical Pathways
Research Reports
The Use of Incremental Cost-Effectiveness Ratio Thresholds in Health Technology Assessment Decisions
10/27/2015
Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...
Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...
...
10/27/2015
Journal of Clinical Pathways
Feature
The Evolution of Clinical Pathways for Oncology
10/27/2015
Abstract: A substantial portion of total medication costs is represented by the cost of specialty drugs, which only continues to rise. Oncology, in particular, is one of the three most costly specialty therapeutic...
Abstract: A substantial portion of total medication costs is represented by the cost of specialty drugs, which only continues to rise. Oncology, in particular, is one of the three most costly specialty therapeutic...
...
10/27/2015
Journal of Clinical Pathways

Column

Viewpoint
The Current Cost of Cancer Drugs: Physician, Payer and Government Concerns Grow
10/27/2015
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The...
10/27/2015
Journal of Clinical Pathways
Counterpoint
To Increase Innovation and Make Drugs More Affordable, Deregulate
10/27/2015
Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...
Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...
Are...
10/27/2015
Journal of Clinical Pathways

Insights

Interview
Evidence for Action and Funding the Future of American Population Health and Health Care
10/27/2015
JCP Editors
Erin Hagan, MBA, PhD, discusses Evidence for Action, a national program of the Robert Wood Johnson Foundation designed to support high-impact action-oriented research to assess population health and health care outcomes and set priorities for...
Erin Hagan, MBA, PhD, discusses Evidence for Action, a national program of the Robert Wood Johnson Foundation designed to support high-impact action-oriented research to assess population health and health care outcomes and set priorities for...
Erin Hagan, MBA, PhD, discusses...
10/27/2015
Journal of Clinical Pathways
Interview
Developing a Framework to Assess Value in Cancer Care
10/27/2015
Richard Schilsky, MD, FACP, FASCO, spoke with Journal of Clinical Pathways about some of the forces that led to the development of the ASCO Value Framework and considerations that influenced its design.
Richard Schilsky, MD, FACP, FASCO, spoke with Journal of Clinical Pathways about some of the forces that led to the development of the ASCO Value Framework and considerations that influenced its design.
Richard Schilsky, MD, FACP,...
10/27/2015
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

September 2015 Volume 1

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use